Lifileucel (LN-144) showed a favorable overall response rate in patients with pretreated metastatic melanoma, according to initial data from cohort 4 of the phase 2 C-144-01 trial.
Conferences
Reviewing the Risk-Benefit Ratio of Adjuvant and Neoadjuvant Approaches in Melanoma
OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care.
Melanoma tumor syndromes
Recognition of patients with hereditary melanoma is important not only because these individuals require careful surveillance for future primary melanomas, but also because they may be predisposed to multiple other types of malignancies because of their genetic mutation, says Hensin Tsao, M.D., Ph.D., professor of dermatology and director, MGH Melanoma and Pigmented Lesion Center, Massachusetts General Hospital, Harvard Medical School, Boston.
Microbiotica, Cancer Research UK and Cambridge University Hospitals Collaborate in Landmark Cancer Microbiome Study
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, Cancer Research UK and Cambridge University Hospitals NHS Foundation Trust (“CUH”), today announce a collaboration to identify and develop microbiome co-therapeutics and biomarkers for cancer patients receiving immune checkpoint inhibitor therapy.